Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors. by Maletkovic, Jelena et al.
UCLA
UCLA Previously Published Works
Title



















eScholarship.org Powered by the California Digital Library
University of California
Clinical Research Article
Residual Tumor Confers a 10-Fold Increased
Risk of Regrowth in Clinically
Nonfunctioning Pituitary Tumors
Jelena Maletkovic,1 Asmaa Dabbagh,1 Dongyun Zhang,1 Abdul Zahid,1
Marvin Bergsneider,2 Marilene B. Wang,3 Michael Linetsky,4 Noriko Salamon,4
William H. Yong,5 Harry V. Vinters,5 and Anthony P. Heaney1,2
1Department ofMedicine,UCLA–DavidGeffenSchool ofMedicine, LosAngeles,California 90095; 2Department
of Neurosurgery, UCLA–DavidGeffen School ofMedicine, LosAngeles, California 90095; 3Department ofHead
& Neck Surgery, UCLA–David Geffen School of Medicine, Los Angeles, California 90095; 4Department of
Neuroradiology, UCLA–David Geffen School of Medicine, Los Angeles, California 90095; and 5Department of
Pathology and Laboratory Medicine, UCLA–David Geffen School of Medicine, Los Angeles, California 90095
ORCiD numbers: 0000-0003-3865-0810 (A. P. Heaney).
Objective: We evaluated tumor recurrence and regrowth rates following endoscopic transnasal
transsphenoidal (TNTS) surgical removal in a consecutive series of clinically nonfunctioning pituitary
adenomas (CNFTs).
Design: Retrospective chart review of clinical, biochemical, and sellar MRI findings in all TNTS
surgeries in patients with CNFT, performed by a single surgeon, between 2008 and 2015 (n 5 280).
Patients: Ninety-three patients met eligibility criteria, with complete clinical, biochemical, and im-
aging follow-up for a 3-year minimum.
Results: Of 85 patients who were not irradiated, 3-month postsurgical MRI demonstrated no residual
tumor in 58 of 85 (68.2%), equivocal findings in 12 of 85 (14.1%), and definite residual tumor in 15 of 85
(17.6%) patients. Six of 85 (7.1%) demonstrated tumor regrowth by 3 years, and 2 further patients dem-
onstrated true tumor recurrence at 3 and 6 years after surgery, respectively, for a total recurrence rate of
9.4% (8 of 85). Eight of the 93 patientswere irradiated between 3months and 4 years after pituitary surgery.
In 3 patientswith tumor regrowth, 2 exhibited residual tumor and 1 had no residual findings at the 3-month
postoperative imaging. Overall, Ki-67 labeling index or Knosp grading did not predict recurrence.
Conclusion: Tumor recurrence at 3 years was low (1 of 58; 1.7%) if the 3-month postoperative MRI
showed no residual tumor. The findings support a less frequent imaging schedule for this group.
Patients with definite residual tumor visible at 3 months harbor the greatest risk for tumor growth, but
regrowth does not occur in all patients (6 of 15; 40%).
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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The goals of therapy for pituitary tumors are clinical and biochemical remission and control of
tumor growth. In contrast to functioning tumors, for which biochemical markers complement
imaging assessment and often suggest tumor recurrence before visible tumor is detected on
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imaging, remission and recurrence in clinically nonfunctional tumors (CNFTs) are largely
determined by anatomic imaging.
Studies examining long-term recurrence after endoscopic transnasal transsphenoidal (TNTS)
pituitary tumor removal often include small numbers of patients with variable follow-up du-
ration. In addition, many are confounded by the concomitant use of routine radiotherapy in the
postoperative period for tumor remnants that make clear conclusions on the natural history of
these generally benign tumors difficult [1]. One meta-analysis study estimated that the mean
early postoperative remission rate was 47.3% in CNFTs [2]. Given the high recurrence rates
reported in some studies, some centers submit that most patients with residual postoperative
tumor should routinely be offered radiation therapy following surgical resection.
Several studies have demonstrated that the most reliable predictor of tumor regrowth is the
presence of residual tumor following pituitary surgery. For example, Chen et al. [3] reported a
tumor regrowth rate of 12% when no residual tumor was noted after surgery compared with a
46% rate when postoperative residual tumor was noted. Other studies have also suggested that
younger age, sex, and initial tumor size may also be contributing factors [4].
Although there is no standard protocol, most pituitary centers typically image in the first 3
to 6 months after pituitary surgery and then annually for 3 to 5 years. Thereafter, MRI is
performed less frequently and is guided by the clinical situation in an individualizedmanner.
For example, on the basis of a 2-year follow-up in 51 patients, one study suggested performing
postoperativeMRI at 4 to 6 months and then 12, 24, and 36months after surgery, followed by
imaging at 5 and 10 years [5]. Currently, we perform MRI of the pituitary 3 and 12 months
after surgery and then annually for 3 to 5 years; this equates to an average cost of $5400 per
patient for these six MRI studies.
The neurosurgical approach to the sella has changed substantially in the past 10 to 15
years, with the more widespread use of endoscopic approaches. These have enabled direct
visualization of tumor and normal pituitary tissue. Some researchers have advocated that the
endoscopic approach facilitates more extensive tumor removal, although not all surgeons
accept this notion [6]. In light of these advances in surgical technique and the substantial cost
and anxiety that imaging studies induce in some patients, we sought to evaluate long-term
remission rates in a recent cohort of patients with CNFTs and ask whether our current
imaging schedule was appropriate and cost-effective for all patients.
1. Methods
A. Study Design
The institutional review board approved this retrospective chart review study of all patients
undergoing first endoscopic TNTS for pathologically confirmed CNFTs (n 5 280) between
2008 and 2015 at the UCLA Medical Center by an experienced single surgeon (M.B.), with
stable surgical outcomes across the study. Patients’ demographic characteristics, endocri-
nologic evaluation, intraoperative findings, histopathological assessment, and preoperative
and serial postoperative MRI studies were reviewed. One hundred eighty-five patients had
incomplete clinical, endocrine, and/or imaging assessment for less than the minimum 3-year
follow-up period and were excluded, as were 2 patients who underwent surgery for clinically
nonfunctioningmicroadenomas. After exclusions, 93 patients were eligible for study analysis.
The core study focused on a mandatory 3-year follow-up for all 93 patients, although we did
have longer-term follow-up in 58 of 93 (62%) patients; 4 years, n5 21; 5 years, n5 15; 6 years,
n5 12; 7 years, n5 5; 8 years, n5 4; 10 years, n5 1; this was also evaluated in determining
recurrence and regrowth rates.
B. Clinical and Endocrine Assessment
Clinically nonfunctioning pituitary adenoma was diagnosed on the basis of clinical history
characteristics, physical findings and endocrinologic evaluation results, imaging findings,
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and confirmation by histopathology. Early-morning laboratory sampling for prolactin, TSH,
free T4, ACTH, cortisol, LH, FSH, IGF-1, and testosterone (men only) was performed in all
patients by using commercially available assays. Endocrine laboratory assessment was
performed 2 to 3 months after surgery and then annually unless clinical, biochemical, or
imaging evidence of residual disease demanded more frequent biochemical monitoring.
C. Imaging Studies
All MRI studies included pre- and postcontrast T1- and T2-weighted images in sagittal and
coronal planes. Cavernous sinus invasion was determined by using the Knosp scale; grades 0,
1, and 2 indicated no invasion; grade 3a, probable invasion; and grades 3b and 4, definite
invasion [7]. A 3-month postoperative MRI study was routinely obtained as the baseline
comparative study, and findings from that study were categorized into one of three groups:
group 1, patients with no residual tumor; group 2, patients who had an equivocal MRI on
which the neuroradiologist could not differentiate postoperative change from possible re-
sidual tumor; and group 3, patients with definite residual tumor. The subsequent MRI
examinations at 1, 2, and 3 years were compared with all prior studies, including the 3-month
postoperative baseline study, and were categorized into one of two outcomes: outcome 1,
stable compared with 3-month postoperative imaging (no recurrence or no growth); outcome
2, growth of the residual tumor or de novo growth (true recurrence).
D. Surgical Technique
All surgeries were performed by a dedicated team consisting of a neurosurgeon (M.B.) and a
head and neck surgery skull-base rhinologist (M.B.W.). A binaural endoscopic approach that
incorporated a wide sellar exposure was used. Whenever possible, a pseudocapsular dis-
section technique [8] was used to excise the pituitary tumor. Cavernous sinus exploration was
performed in all cases where cavernous sinus invasion was evident.
E. Histopathologic Analysis
Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin. Im-
munostaining for LH, FSH, TSH, GH, prolactin, and ACTH, as well as Ki-67, was performed
on 5-mm sections of the tumor. Ki-67 was scored by the observer estimating percentage of Ki-
67–positive nuclei compared with all the nuclei as stained with hematoxylin and eosin.
Tumors were classified by using the World Health Organization classification (2004) by our
neuropathologists (W.H.Y. and H.V.V.).
F. Statistics
Demographic differences between ages and tumor sizes of the included and excluded patients
were assessed by two-sided Student t test, and the difference between sexes was analyzed




Table 1 shows the demographics and tumor characteristics of the study cohort of 93 patients,
which were similar to those of the 187 excluded patients and demonstrates similar sex and
age distribution and tumor size at presentation. Three of the clinically nonfunctional
macroadenomas were so-called giant macroadenomas (.4 cm diameter), 55 were gonado-
troph tumors, 6 were “silent” corticotroph tumors, and 32were null cell tumors. As depicted in
Fig. 1A, among 85 nonirradiated patients, pituitary MRI imaging 3 months after surgery
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demonstrated no residual tumor in 58 patients (68.2%; group 1), equivocal MRI findings
regarding postoperative changes vs residual tumor in 12 patients (14.1%; group 2), and
definite residual tumor in the remaining 15 patients (17.6%; group 3). Seven of the 85
patients (8.2%) exhibited tumor growth across the “core” 3-year follow-up imaging
study and one patient demonstrated recurrence at 6 years, for a total recurrence rate of
9.4% (8 of 85 patients) over 3 to 10 years. Of these regrowth/recurrent cases, 6 had
evidence of residual tumor at 3-months postoperative imaging, whereas no residual
tumor was observed in the remaining 2 patients at 3-month postoperative MRI.
Eight of the 93 patients were irradiated between 3 months and 4 years after pituitary
surgery, and no tumor growth occurred following radiation therapy (Fig. 1B). Seven of eight
patients (87.5%) exhibited residual tumor on the 3-month postoperative imaging study, and
no residual findings were noted in the eighth patient. In 3 of these patients, interval tumor
growth was documented before radiation administration. The remaining 5 patients did not
exhibit tumor growth, and indications for radiation included large-volume residual tumor
with (n 5 3) or without (n 5 2) risk of optic chiasm compression should minimal tumor
growth occur.
B. Ki-67 Labeling Index as Predictor of Postoperative Tumor Growth/Recurrence
Ki-67 labeling index (Ki-67 LI) was available in 88 of the 93 patients, as tumors exhibiting
substantial apoplexy/necrosis or heavy inflammatory cell infiltratemade assessment of Ki-67
LI unreliable. As depicted in Fig. 2A and 2B, Ki-67 LI ranged from 1% to 12.5% (mean Ki-67
LI 6 SD, 2.6% 6 2.1%; n 5 88). There was no difference in tumors that exhibited tumor
growth of residual (n 5 8) or true recurrence (n 5 2) (mean Ki-67 LI, 2.9% 6 1.9%; n 5 10)
compared with those that did not exhibit tumor growth by 3 years (mean Ki-67 LI, 2.6% 6
2.2%; n 5 78; P 5 NS). In addition, Ki-67 LI did not differ in tumors from nonirradiated
patients (mean Ki-67 LI, 2.6% 6 2.2%; n 5 80) in comparison with tumors from those who
received radiation (mean Ki-67 LI, 3.1%6 2.0%; n5 8; P5NS). The highest KI-67 LI, of 10%
to 12.5%, was seen in 2 patients (1 who had no residual at 3 months and 1 who had equivocal
findings at 3 months), but neither patient exhibited tumor regrowth across the 3-year follow-
up. Twenty-four of our 88 evaluated patients had a Ki-67 LI $ 3%, which some studies
suggest indicates a higher risk of recurrence. Fourteen of these 24 patients had no residual
tumor at 3 months, and none demonstrated true recurrence over 3 years; 4 had an equivocal
3-month MRI study and none of these recurred. Interestingly, of 6 patients who had Ki-67
LI $ 3% and had residual tumor at 3 months, 4 exhibited tumor growth over the 3-
year follow-up.
C. Knosp Score Prediction of Tumor Resection and Recurrence Risk
In the 59 patients who had a 3-month postoperative MRI showing no residual tumor, Knosp
grading of their preoperative MRI (Fig. 3A and 3B) demonstrated that 51 (86%) were non-
invasive [G0, n5 16 (27%); G1, n5 24 (41%); and G2, n511 (19%)], 5 cases (8%) had probable
cavernous sinus (CV) invasion (G3a), and 3 tumors (5%) exhibited definite cavernous sinus
Table 1. Demographic Characteristics and Tumor Size in the 93 Included Patients and 187 Ineligible
Patients
Variable Excluded Patients (n 5 187) Study Patients (n 5 93)
Men/women, n/n 84/103 39/54
Age range (mean), y 19–83 (56.2) 21–82 (56.8)
Tumor size range (mean), mm 6–72 (25.6) 10–50 (24.6)
Excluded patients were ineligible because of incomplete clinical, endocrine, and/ or imaging studies or micro-
adenomas (n 5 2). Age and tumor size did not significantly differ between groups.
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invasion [G4, n5 3 (5%)] (Fig. 3A). In the 22 patients who exhibited definite residual tumor on
the 3-month postoperative MRI, Knosp grading indicated 12 (55%) tumors were noninvasive
(G0, n 5 3; G1, n 5 3; G2, n 5 6), 5 cases exhibited probable CV invasion (23%, G3a), and 5
tumors were invasive (23%, G4) (Fig. 3A). Of the 8 patients who exhibited growth from residual
tumor seen at 3 months across the 3-year follow-up period, 6 were noninvasive (G0, n5 2; G1,
Figure 1. Schematic flowchart of (A) nonirradiated and (B) irradiated patients assigned
to groups 1, 2, and 3 based on imaging studies at 3 mo and their imaging study at 3-y
follow-up. Group 1, no visible residual tumor on 3-mo postoperative MRI; group 2,
equivocal 3-mo postoperative MRI wherein the neuroradiologist could not differentiate
postoperative change from possible residual tumor; group 3, definite residual tumor on
3-mo postoperative MRI.
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n5 1; G2, n5 3), 1 case had probable CV invasion (G3a), and 1 case had definite CV invasion
(G4). Interestingly, in 2 patients who exhibited true recurrence over 3 years (i.e., 3-month
postoperative MRI showed no evidence of residual tumor), both tumors were invasive (G4,
n 5 2) (Fig. 3B).
3. Discussion
Our experience confirms that TNTS is an overall excellentmodality for treatment of clinically
nonfunctioning pituitary tumors, with an excellent, comparatively low recurrence rate. It also
reaffirms the extensive literature that surgical experience is an important factor in attaining
initial gross total resection (GTR), which is key to reducing rates of later recurrence in these
tumors [3, 9, 10]. We chose to conduct our study in patients who had undergone trans-
sphenoidal surgery by a single surgeon to reduce confounders due to variation in experience
and technique. Although this, along with a mandated minimum 3-year careful follow-up,
somewhat limited our sample size, it allowed us to obtain complete data for all included
patients. As noted, we did assess longer-term follow-up imaging when available in many of
our patients, in one case out to 10 years.
In our 85 nonirradiated patients, true recurrence was observed in 1 patient (1.7%) at 3
years; 1 other patient exhibited recurrence at 6 years, for total true recurrence rate of
Figure 2. Distribution of Ki-67 LI in 88 of 93 patients based on (A) pituitary MRI at 3 mo
postoperatively: definite tumor, equivocal MRI, no residual; and (B) outcome at 3 y after
surgery: true recurrence, tumor growth, no tumor growth. The cycle mark indicates
nonirradiated patients and cross mark indicates irradiated patients. The red symbols
indicate Ki-67 LI $3%.
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(3.4%) (2 of 58) across an average follow-up of 4.5 years (range, 3 to 10 years). In 15 patients
with definite visible residual tumor at 3 months, regrowth was observed in 6 of 15 (40%) at
3 years; no further patients with tumor growth were noted across the average follow-up
period of 4.5 years. In the remaining 8 patients who underwent tumor-directed radiation
therapy, 7 had definite residual and 1 exhibited no residual MRI image on 3-month
postoperative imaging. Growth of residual tumor before radiation was documented in 3
patients (37.5%), and no patient exhibited tumor growth following radiation therapy. As
noted in the Results section, radiation was recommended in the remaining 5 patients
because of a significantly sized tumor remnant (n 5 4), with eminent risk of optic chiasm
compression in 2 of these patients. Considering all patients, both nonradiated and irra-
diated, we observed an overall regrowth/recurrence rate of 10.7% (10 of 93 patients) at
Figure 3. Knosp grading in 93 patients grouped according to (A) pituitary MRI 3 mo
postoperatively: definite tumor, equivocal MRI, no residual; and (B) outcome at 3 y after
surgery: true recurrence, tumor growth, no tumor growth. Knosp 0, 1, and 2, no cavernous
sinus invasion; Knosp 3a, uncertain CV invasion; Knosp 3b and 4, definite CV invasion.
Number of irradiated patients is depicted in red brackets.
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3 years, with 1 further patient developing true recurrence at 6 years, for total recurrence/
regrowth in 11 of 93 (11.8%). This rate is very similar to that reported by others [3, 9].
This latter type of experience understandably has led some centers to routinely recom-
mend radiotherapy in all patients with residual tumor after TNTS [10]. In CNFTs, the
goal of surgery is often to decompress structures, such as the optic chiasm and therefore
GTR may not be considered as critical as in hormone-secreting tumors, particularly
in centers where postoperative radiation is the long-standing practice. In tumors in-
volving the cavernous sinuses, extending to encase the internal carotid arteries and/or
extensive suprasellar extension, the risks of a potentially more aggressive surgical effort
must be balanced with the morbidity, or lack thereof, of leaving residual nonfunctioning
tumor. We believe that careful selection of patients to undergo attempted complete re-
section of CNFTs is appropriate in certain circumstances where the tumor can be safely
fully resected.
The 23-fold difference in recurrence/regrowth rates at 3 years in our patients with no
residual tumor (true recurrence, 1 of 58, 1.7%) vs thosewith definite visible tumor at 3months
(6 of 15, 40%) is striking and not dissimilar to that reported by Dallapiazza et al. and others
(0% to 6% in patients with no residual), increasing to 42% to 53% with intrasellar remnant
tumor and up to 80% with extrasellar tumor, emphasizing that GTR of the tumor itself, as
documented by no residual tumor seen on MRI, is the most important determinant of re-
currence risk [9–12].
Some studies have suggested that Ki-67 LI may be helpful in predicting pituitary tumor
progression. A study in 39 patients reported that pituitary adenomas with progression
(regrowthwithin 5 years after initial surgery) had a highermean proliferation index (3.66%6
3.00%; n5 12) than tumors without progression (1.89%6 1.25%; n5 27;P, 0.05) [13]. Other
studies have suggested a Ki-67 LI . 3% to be associated with tumor recurrence [14], but
others report that although this Ki-67 LI threshold of 3% has a high specificity (89.5%), its
sensitivity is comparatively poor (53.8%) [15]. Our study shows that Ki-67 as a standalone
parameter is unreliable, in that most of our tumors with high Ki-67 could be fully resected
with no visible tumor 3months after surgery and, therefore, low risk of recurrence. It could be
argued that we had inadvertently selected out a group of patients with high potential to
regrow early for radiation, and so we also examined that subgroup. Mean Ki-67 LI did not
differ between the radiated group (mean Ki-67 LI, 3.1%6 2.0%; n5 8) and the nonirradiated
cohort (mean Ki-67 LI, 2.6%6 2.2%; n5 80). Overall, our results suggest caution with the use
of Ki-67 values alone in guiding clinical decisions, such as indication for radiotherapy after
pituitary surgery.
Our study also confirms that persistence of postoperative residual tumor does not always
mean regrowth of tumor remnant over time, indicating that other factors, such as the
inherent biology of the tumor, play an important role. However, in our series, 4 of 6 tumors
(67%) with demonstrable residual tumor at 3 months and a Ki-67 LI . 3% demonstrated
recurrence. Therefore, it appears the combined information of postoperative radiologic
appearance demonstrating residual tumor and then retrospective review of histopathology
in those cases may have the most clinically useful predictive value. This is consistent with
findings in a recent prospective study by Raverot et al. [16] where several factors regarding
the tumor, including radiologic invasion and pathological markers, are combined to
offer insight into risk of tumor recurrence. Several tumor subtypes that exhibit increased
regrowth/recurrence rates or need for additional surgical or radiation treatments have
been proposed [17, 18]. These include so-called silent corticotroph and/or somatotroph
tumors, wherein hormones can be detected immunohistochemically in the tumor but
clinical signs of hormonal excess are not observed and hormones are not elevated in cir-
culation. More recently, low estrogen receptor a in gonadotroph tumors has been reported
to be associated with higher reintervention rates in male patients [19]. All of these studies
emphasize the importance of obtaining a complete initial tumor resection in reducing risk
of remnant tumor regrowth and in so doing limiting the need for adjuvant therapy,
including radiation.
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Researchers using a revised Knosp classification have reported that patients with grade
3a tumors had higher GTR rates than did those with grade 3b tumors (85% vs 64%), and the
GTR rates in grade 4 tumors was 0%. Using this same modified Knosp classification, we
observed that GTR was possible in some patients with grade 4 tumors, whereas in some
grade 3 tumors, GTR was not attainable. In some cases, this was at least in part due to
adherent properties of the tumor. Our findings also showed that although 2 of 2 (100%) of
our patients who exhibited true recurrence over 3 years had invasive tumors (G4) by Knosp
grading, 7 of 8 tumors that exhibited growth across the 3-year follow-up period did not have
definite evidence of CV invasion on preoperative MRI imaging. Overall, our study indicates
that although Knosp grading may be helpful in surgical planning, it has limited value in
predicting risk of recurrence. Clearly, in addition to internal carotid artery adhesion
and encasement, other anatomic aspects, such as tumor suprasellar extension, can sub-
stantially limit gross total pituitary tumor resection.
A strength of our study is that all included patients had a minimum follow-up period of 3
years, with careful, consistent monitoring of clinical, biochemical, and imaging studies.
However, given that some studies have estimated the residual tumor volume doubling time to
be 3.4 years, the relatively short-term follow-up in some of our patients may have under-
estimated the ultimate full regrowth and recurrence rates [3, 11, 20]. However, we did
have.3 years of follow-up in 58 of 93 patients (62%) (4 years, n5 21; 5 years, n5 15; 6 years,
n5 12; 7 years, n5 5; and 8 years, n5 4), with average 4.5 years of follow-up. Furthermore,
although 20% of recurrent eventsmay occur at least 10 years after surgery, most are typically
observed in the first 3 years. Therefore, our results indicate that if an imaging study at
3 months shows no residual tumor, the risk of subsequent recurrence is reassuringly low at
;1.7% at 3 years and 3.4% overall.
We must acknowledge other limitations in this study, and our conclusions may not be
generalizable to all patients who require surgery for pituitary tumors. For example, because
we are a tertiary referral center and many of our patients come to us for TNTS alone,
thereafter returning to the care of their local endocrinologist, we could capture “complete”
follow-up data for only 93 of 280 patients (33%). It is possible that this introduced bias in our
outcomes, as wemay not have seen all the tumor recurrences. However, generally any patient
who does have recurrence will be referred back to our center. Overall, our data affirm the
importance of GTR at first surgical attempt in limiting recurrence rates. Ultimately, the skill
of the surgeon regardless of the technique (endoscopy vs speculum) is the key determinant of
success, as has been emphasized in a recent white paper on pituitary tumor centers of
excellence [21].
This study has prompted us to re-evaluate our current imaging schedule. As noted, at
3 months, we observed equivocal postoperative MRI findings in 14% of patients. It may be
possible to lower the frequency of indeterminate MRI studies by performing this post-
operative MRI first at 6 months and then annually for 3 to 5 years. Using a standardized
MRI protocol with the same orientation of coronal sections can also help detect subtle
regrowth of tumor remnants. Our data would suggest that if MRI findings are negative at
3 months and 1 year, imaging could then be deferred for at least 2 years and scanning
intervals thereafter could be reduced to every 3 to 5 years in most patients unless symptoms
suggest otherwise. Additionally, in some patients in whom residual lesions are T2 en-
hancing, gadolinium injection can be spared and residual tumor monitored without con-
trast. This strategy of reduced image frequency with sparing use of gadolinium in suitable
patients would provide a substantial health care cost saving and lessen test anxiety
for patients.
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